Valeritas’ V-Go® Demonstrates Positive Impact in Diabetes Quality Performance Measures in an Older Adult Population
BRIDGEWATER, N.J., May 22, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, today announced additional data from the VERDICT study at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting. The data demonstrated that V-Go therapy resulted in better glycemic control and improved attainment of Quality Performance Measures (QPM) and was well tolerated.
The data used in this analysis was taken from the VERDICT study, a real-world retrospective analysis of electronic health records from a large specialized diabetes center. According to HEDIS, which sets QPMs, A1c >9% is considered poor diabetes control. After five months of V-Go use, significant reductions in A1c of 1.5% were observed, and nearly twice as many patients achieved evaluated A1c QPM.
“The VERDICT study demonstrates that significantly more patients achieved better control and attained improved quality metrics. We will continue to partner with clinicians to improve patient outcomes and quality of care delivered using V-Go as a standard way to deliver basal-bolus insulin therapy,” said John Timberlake, President and Chief Executive Officer of Valeritas.
About Valeritas Holdings, Inc.
Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, V-Go® Wearable Insulin Delivery device, is a simple, affordable, all-in-one basal-bolus insulin delivery option for patients with type 2 diabetes that is worn like a patch and can eliminate the need for taking multiple daily shots. V-Go administers a continuous preset basal rate of insulin over 24 hours, and it provides discreet on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Marlborough, Massachusetts.
This press release may contain forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to Valeritas technologies, business and product development plans and market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue Valeritas’ business and product development plans, Valeritas’ expected cash burn rate and its ability to continue to increase new and total prescription growth, the effects of the reverse stock split on the trading price of Valeritas’ common stock, in both the short and long-term; the inherent uncertainties associated with developing new products or technologies, the ability to continue to commercialize the V-Go® Wearable Insulin Delivery device with limited resources, competition in the industry in which Valeritas operates and overall market conditions. Statements or claims made by third parties regarding the efficacy or functionality of V-Go as compared to other products are statements made by such individual and should not be taken as evidence of clinical trial results supporting such statements or claims. Any forward-looking statements are made as of the date of this press release, and Valeritas assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents Valeritas files with the SEC available at www.sec.gov.
Investor Contacts:Lynn Pieper Lewis or Greg ChodaczekGilmartin Group646-924-1769 email@example.com
Media Contact:Kevin KnightKnight Marketing Communications, Ltd.206-451-4823 firstname.lastname@example.org